Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?

Trastuzumab has recently been introduced as a treatment for HER2-positive metastatic and/or unresectable gastric cancer (MUGC); however, compared with breast cancer, some issues concerning HER2 and trastuzumab therapy for gastric cancer remain unclear. A 74-year-old woman received trastuzumab-contai...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishimine, Yu, Goto, Akira, Watanabe, Yoshito, Yajima, Hidetaka, Nakagaki, Suguru, Yabana, Takashi, Adachi, Takeya, Kondo, Yoshihiro, Kasai, Kiyoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4393931/
https://www.ncbi.nlm.nih.gov/pubmed/25893119
http://dx.doi.org/10.1155/2015/132030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4393931/
https://www.ncbi.nlm.nih.gov/pubmed/25893119
http://dx.doi.org/10.1155/2015/132030

Ejemplares similares